PEGylation of therapeutic proteins

Biotechnology Journal - Tập 5 Số 1 - Trang 113-128 - 2010
Simona Jevševar1, Menči Kunstelj1, Vladka Gaberc Porekar2
1Lek Pharmaceuticals d.d., a Sandoz Company, Biopharmaceuticals, Ljubljana, Slovenia
2National Institute of Chemistry, Ljubljana, Slovenia

Tóm tắt

AbstractSince the first PEGylated product was approved by the Food and Drug Administration in 1990, PEGylation has been widely used as a post‐production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins. Applicability and safety of this technology have been proven by use of various PEGylated pharmaceuticals for many years. It is expected that PEGylation, as the most established technology for extension of drug residence in the body, will play an important role in the next generation therapeutics, such as peptides, protein nanobodies and scaffolds, which due to their diminished molecular size need half‐life extension. This review focuses on several factors important in the production of PEGylated biopharmaceuticals enabling efficient preparation of highly purified PEG‐protein conjugates that have to meet stringent regulatory criteria for their use in human therapy. Areas addressed are PEG properties, the specificity of PEGylation reactions, separation and large‐scale purification, the availability and analysis of PEG reagents, analysis of PEG‐protein conjugates, the consistency of products and processes and approaches used for rapid screening of pharmacokinetic properties of PEG‐protein conjugates.

Từ khóa


Tài liệu tham khảo

Szymkowski D. E., 2005, Creating the next generation of protein therapeutics through rational drug design., Curr. Opin. Drug Discov. Dev., 8, 590

Abuchowski A., 1977, Alteration of immunological properties of bovine serum‐albumin by covalent attachment of polyethylene‐glycol., J. Biol. Chem., 252, 3578, 10.1016/S0021-9258(17)40291-2

Abuchowski A., 1977, Effect of covalent attachment of polyethylene‐glycol on immunogenicity and circulating life of bovine liver catalase., J. Biol. Chem., 252, 3582, 10.1016/S0021-9258(17)40292-4

10.1016/S0022-3476(88)80271-3

10.1038/nrd1955

10.1080/14628840310017177

10.1021/bc050237q

10.1016/j.addr.2007.06.011

10.1517/17425240802650568

10.1517/14728210902907847

10.1517/17425247.5.4.371

10.1016/j.cbpa.2009.04.627

10.1016/j.coph.2008.06.007

10.1016/j.copbio.2007.04.010

10.1007/s00253-007-1142-2

10.1007/s00430-009-0116-7

10.1002/jps.21278

10.1517/17460441.3.11.1293

10.1177/088391159701200303

10.1007/s00253-001-0850-2

Mehvar R., 2000, Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation., J. Pharm. Pharm. Sci., 3, 125

10.1016/0142-9612(90)90070-7

10.1016/S0169-409X(03)00108-X

10.1016/j.progpolymsci.2007.05.008

10.1016/j.addr.2007.02.001

10.1021/bc050322y

10.1021/bc000082g

10.1016/0169-409X(91)90041-A

10.1186/ar1861

10.1016/j.ymthe.2005.09.014

10.1016/j.jconrel.2007.02.010

10.1021/bc990147j

10.1016/j.molimm.2008.08.276

10.1093/toxsci/42.2.152

10.1021/bc000119x

10.1159/000233309

10.1016/S0169-409X(02)00022-4

10.1038/nrd1033

10.1200/JCO.2002.02.051

10.1016/j.ijpharm.2005.06.007

Abuchowski A., 1984, Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol‐asparaginase conjugates., Cancer Biochem. Biophys., 7, 175

10.1111/j.1470-8744.1992.tb00198.x

Zalipsky S. Seltzer R. Nho K. Succinimidyl carbonates of polyethylene glycol in: Dunn R. L. Ottenbrite R. M. (Ed.) Polymeric Drugs and Drug Delivery Systems American Chemical Society Wasington DC 1991.

10.1016/S0169-409X(02)00023-6

10.2174/1381612043452613

10.1021/bc070123

10.1021/bc050172r

10.1021/bc049713n

10.1093/protein/gzm015

10.1021/bc0601471

10.1038/nchembio786

10.1016/j.bmcl.2004.12.065

10.1016/S0169-409X(02)00024-8

10.1016/j.addr.2007.06.015

10.1093/glycob/cwl004

10.1016/j.ces.2005.04.040

Kusterle M., 2008, Size of pegylated protein conjugates studied by various methods., Acta Chim. Sloven., 55, 594

10.1002/bit.21482

10.1016/S0021-9673(00)00739-1

Seely J. E., 2005, Making site‐specific PEGylation work., Biopharm Int., 18, 30

10.1016/j.ab.2009.03.023

10.1038/11717

10.1016/S1046-5928(03)00055-X

10.1016/j.jbiotec.2005.02.015

10.1016/j.chroma.2007.02.051

10.1016/S0169-409X(03)00112-1

10.1002/bit.21020

10.1016/j.chroma.2009.05.043

10.1016/j.progpolymsci.2005.12.001

10.1021/bc049843w

Gaberc‐Porekar V., 2008, Obstacles and pitfalls in the PEGylation of therapeutic proteins., Curr. Opin. Drug Discov. Dev., 11, 242

10.1016/j.addr.2007.04.017

10.1016/0003-2697(92)90460-O

10.1016/S0169-409X(02)00027-3

10.1002/mas.20129

10.1016/j.jpba.2007.02.036

10.1021/bc800427n

10.2165/00003088-200544040-00001

Roovers R. C., 2007, Nanobodies in therapeutic applications., Curr. Opin. Mol. Ther., 9, 327

Thông tin
Thông tin xuất bản

Biotechnology Journal

Tập 5 Số 1

113-128

Thông tin tác giả